Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM), a biopharmaceutical company focused on advancing innovative therapies for neurodegenerative and metabolic disorders, announced that it has engaged Stocks.news through IR Agency LLC for investor relations and consulting services. The agreement, effective June 8, 2026, is set for a six-month term and includes a fee of US$250,000. The agency will provide services such as company profile creation, media distribution, digital community development, news marketing, and lead generation campaigns.
The engagement is part of Quantum BioPharma's strategy to increase its visibility among investors and the broader financial community. IR Agency LLC is described as arm's-length to the company, holding no direct or indirect equity interest in its securities, ensuring an unbiased approach to investor relations.
Quantum BioPharma is dedicated to building a portfolio of innovative assets and biotech solutions for challenging conditions, including neurodegenerative diseases, metabolic disorders, and alcohol misuse disorders. The company's lead compound, Lucid-MS, developed through its wholly owned subsidiary Lucid Psycheceuticals Inc., is a patented new chemical entity shown to prevent and reverse myelin degradation in preclinical models of multiple sclerosis. This compound targets the underlying mechanism of the disease, offering potential disease-modifying effects.
Additionally, Quantum invented UNBUZZD and spun out its over-the-counter version to Unbuzzd Wellness Inc., led by industry veterans. Quantum retains a 19.84% ownership stake in Unbuzzd as of March 31, 2026, and is entitled to royalty payments of 7% of sales from unbuzzd until payments total $250 million, after which the royalty drops to 3% in perpetuity. Quantum retains 100% of the rights to develop similar products or alternative formulations for pharmaceutical and medical uses.
This announcement is significant as it signals Quantum BioPharma's commitment to effectively communicate its scientific advancements and corporate milestones to the investment community. By partnering with a specialized investor relations firm, the company aims to enhance its profile and potentially attract a broader base of investors. The move comes at a time when biotech companies are increasingly focusing on investor outreach to support their research and development efforts.
For more information about Quantum BioPharma and its latest news, visit the company's newsroom at https://ibn.fm/QNTM. The full press release regarding this engagement is available at https://ibn.fm/iBZrw.
